BioXcel Therapeutics is trading 13.14% down now at $0.14 after its August 27, 2026 Chapter 11 filing and proposed sale of substantially all assets to Teva.
- The company entered a court-supervised sale process, with Teva as stalking-horse bidder; Reuters reported estimated liabilities of $100 million to $500 million, intensifying uncertainty for equity holders.
- Shares fell 74.76% on August 28 and 10.25% on August 31. Broader risk-off sentiment adds pressure, but the move is primarily company-specific.